# A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

> **NCT01110317** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 49 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** paliperidone palmitate 100 mg

## Key facts

- **NCT ID:** NCT01110317
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110317, "A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01110317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*